Tammo Lambert Tergast

Tammo Lambert Tergast

Auto-generated profile, based on publicly available information

Tammo Lambert Tergast

Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2022 in Liver International
Verified
Journal Article
Open access
HWHeiner Wedemeyer
Heiner Wedemeyer
TTTammo L. Tergast
Tammo L. Tergast
JLJeffrey Lazarus
Jeffrey Lazarus
HRHomie Razavi
Homie Razavi
KBKostas Bakoyannis
Kostas Bakoyannis
AHAngelos Hatzakis
Angelos Hatzakis
In 2016, the Hepatitis B and C Public Policy Association (HepBCPPA), gathered all the main stakeholders in the field of hepatitis C virus (HCV) to launch the now landmark HCV Elimination Manifesto, calling for the elimination of HCV in the EU by 2030. Since then, many European countries have made progress towards HCV elimination. Multiple programmes—from the municipality level to the EU level—were launched, resulting in an overall decrease in viremic HCV infections and liver‐related mortality. However, as of 2021, most countries are not on track to reach the 2030 HCV elimination targets set by the WHO. Moreover, the COVID‐19 pandemic has resulted in a decrease in HCV diagnoses and fewer direct‐acting antiviral treatment initiations in 2020. Diagnostic and therapeutic tools to easily diagnose and treat chronic HCV infection are now well established. Treating all patients with chronic HCV infection is more cost‐saving than treating and caring for patients with liver‐related complications, decompensated cirrhosis or hepatocellular carcinoma. It is more important than ever to reinforce and scale‐up action towards HCV elimination. Yet, efforts urgently need the dedicated commitment of policymakers at all governmental and policy levels. Therefore, the third EU Policy Summit, held in March 2021, featured EU parliamentarians and other key decision makers to promote dialogue and take strides towards securing wider EU commitment to advance and achieve HCV elimination by 2030. We have summarized the key action points and reported the ‘Call‐to‐Action’ statement supported by all the major relevant European associations in the field.

3 January 2025 in Hepatology
Verified
Journal Article
Closed access
MKMartin A. Kabelitz
Martin A. Kabelitz
LHLukas Hartl
Lukas Hartl
GSGolda Schaub
Golda Schaub
ATAnja Tiede
Anja Tiede
HRHannah Rieland
Hannah Rieland
BMBenjamin Maasoumy
Benjamin Maasoumy
Background & Aims: Clinically-significant portal hypertension (CSPH) in liver cirrhosis patients can lead to refractory ascites. A transjugular-intrahepatic-portosystemic shunt (TIPS) treats CSPH but may cause overt hepatic encephalopathy (oHE). Our aim was to determine the optimal reduction of the portal pressure gradient (PPG) via TIPS to control ascites without raising oHE risk. Approach: This multicenter study screened 1509 patients from three European centers (Hannover, Vienna, Hamburg) undergoing TIPS-implantation between 2000-2023. Patients with TIPS-indications other than refractory ascites/hepatic hydrothorax, vascular-liver-disease, hepatocellular-carcinoma or insufficient PPG data were excluded. PPG was measured before and after TIPS insertion. Outcome data was assessed up to one year after TIPS-insertion. Analyses were conducted utilizing a modern machine leaning model, namely a competing-risk (CR) random survival forest (RSF), partial-dependence-plots (PDP) and CR-analyses with liver transplantation/death as competitors. The cohort was divided into a 60% derivation and 40% validation cohort. Results: Overall, 729 patients (median MELD: 13 (IQR 10-16), 66% male, 23% oHE before TIPS) were analyzed. The derivation cohort comprised 438 and validation cohort 291 patients. The optimal PPG reduction, determined by maximally selected Grays-statistic and PDP of the RSF, was 60-80%. In this range, patients showed significantly fewer hepatic decompensations due to ascites (HDA) (sHR: 0.7 [0.52-0.96]) with similar oHE incidences (sHR: 0.92 [0.67-1.27]). The PPG range was confirmed in the validation cohort (HDA: sHR: 0.66 [0.46-0.96]; oHE: sHR: 0.89 [0.61-1.32]). Conclusions: A targeted PPG reduction of 60-80% showed significantly reduced HDA without increased oHE risk. Therefore, PPG reduction within this range could be a valid reduction target. Export

6 July 2023 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
TTTammo L. Tergast
Tammo L. Tergast
MGMarie Griemsmann
Marie Griemsmann
LSLena Stockhoff
Lena Stockhoff
KPKerstin Port
Kerstin Port
BHBenjamin Heidrich
Benjamin Heidrich
BMBenjamin Maasoumy
Benjamin Maasoumy
Importance: The potential association of low-volume paracentesis of less than 5 L with complications in patients with ascites remains unclear, and individuals with cirrhosis and refractory ascites (RA) treated with devices like Alfapump or tunneled-intraperitoneal catheters perform daily low-volume drainage without albumin substitution. Studies indicate marked differences regarding the daily drainage volume between patients; however, it is currently unknown if this alters the clinical course.Objective: To determine whether the incidence of complications, such as hyponatremia or acute kidney injury (AKI), is associated with the daily drainage volume in patients with devices.Design, Setting, and Participants: This retrospective cohort study of patients with liver cirrhosis, RA, and a contraindication for a transjugular intrahepatic portosystemic shunt who received either device implantation or standard of care (SOC; ie, repeated large-volume paracentesis with albumin infusion), and were hospitalized between 2012 and 2020 were included. Data were analyzed from April to October 2022.Interventions: Daily ascites volume removed.Main outcomes and Measures: The primary end points were 90-day incidence of hyponatremia and AKI. Propensity score matching was performed to match and compare patients with devices and higher or lower drainage volumes to those who received SOC.Results: Overall, 250 patients with RA receiving either device implantation (179 [72%] patients; 125 [70%] male; 54 [30%] female; mean [SD] age, 59 [11] years) or SOC (71 [28%] patients; 41 [67%] male; 20 [33%] female; mean [SD] age, 54 [8]) were included in this study. A cutoff of 1.5 L/d or more was identified to estimate hyponatremia and AKI in the included patients with devices. Drainage of 1.5 L/d or more was associated with hyponatremia and AKI, even after adjusting for various confounders (hazard ratio [HR], 2.17 [95% CI, 1.24-3.78]; P = .006; HR, 1.43 [95% CI, 1.01-2.16]; P = .04, respectively). Moreover, patients with taps of 1.5 L/d or more and less than 1.5 L/d were matched with patients receiving SOC. Those with taps of 1.5 L/d or more had a higher risk of hyponatremia and AKI compared with those receiving SOC (HR, 1.67 [95% CI, 1.06-2.68]; P = .02 and HR, 1.51 [95% CI, 1.04-2.18]; P = .03), while patients with drainage of less than 1.5 L/d did not show an increased rate of complications compared with those receiving SOC.Conclusions and Relevance: In this cohort study, clinical complications in patients with RA performing low-volume drainage without albumin infusion were associated with the daily volume drained. Based on this analysis, physicians should be cautious in patients performing drainage of 1.5 L/d or more without albumin infusion.

9 November 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
TTTammo L. Tergast
Tammo L. Tergast
BSBenjamin Schulte
Benjamin Schulte
MGMarie Griemsmann
Marie Griemsmann
JKJulia Kahlhöfer
Julia Kahlhöfer
PDPetra Dörge
Petra Dörge
BMBenjamin Maasoumy
Benjamin Maasoumy
Summary: Background: Acute kidney injury (AKI) is a frequent complication in patients with decompensated cirrhosis. Studies reported conflicting results regarding the nephrotoxic potential of iodinated contrast medium (CM) for computer tomography (CT).Aim: To investigate the impact of diagnostic CM application on kidney function in patients with decompensated cirrhosis.Methods: First, we evaluated the impact of diagnostic CM‐CT on AKI incidence in a cross‐sectional approach. Second, we analysed 28‐day AKI incidence post‐CM‐CT in patients with impaired kidney function (i.e., creatinine >133 μmoL/L). Third, we excluded all patients with relevant interventions besides CM‐CT. All remaining patients were matched via propensity score matching (PPSM) and further analysed. Last, we validated the results in an independent dataset of prospectively collected registry data of 118 patients with decompensated cirrhosis. Here, plasma samples were analysed regarding neutrophil‐gelatinase‐associated‐lipocalin (NGAL).Results: Of the 611 included patients, 98 (16%) received CM‐CT. CM‐CT was not associated with AKI in the cross‐sectional approach (CM‐CT:8% vs. no CM‐CT:15%; p = 0.08). Furthermore, CM‐CT was not associated with higher 28‐day AKI incidence among patients with impaired kidney function (HR:0.79; 95% CI 0.45–1.38; p = 0.40). The PPSM cohort revealed no association between CM‐CT and AKI or severe AKI (HR:1.28, p = 0.45 and HR:1.62; p = 0.43). Moreover, CM‐CT did not result in worsening of kidney function after CM application. In the validation cohort, CM‐CT was also not linked to AKI (p = 0.85) and NGAL levels were not increased in those with CM‐CT (CM‐CT:309 ng/ml vs. No CM‐CT:266 ng/ml, p = 0.35).Conclusion: Decompensated cirrhosis per se should not preclude diagnostic CM‐CT.

27 August 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
ATAnja Tiede
Anja Tiede
LSLena Stockhoff
Lena Stockhoff
HRHannah Rieland
Hannah Rieland
ZLZhaoli Liu
Zhaoli Liu
JMJim B. Mauz
Jim B. Mauz
BMBenjamin Maasoumy
Benjamin Maasoumy
Summary: Background and Aims: Non‐selective beta‐blockers (NSBB) are a well‐established treatment in patients with clinically significant portal hypertension. However, their potential role after insertion of a transjugular intrahepatic portosystemic shunt (TIPS) still needs to be determined. Of note, recent studies suggested that favourable anti‐inflammatory effects of NSBB might be independent from pressure reduction. This study aimed to evaluate whether NSBB‐treatment is associated with amelioration of systemic inflammation (SI), hepatic decompensation and survival after TIPS‐insertion.Methods: In a retrospective study comprising 305 consecutive patients, we investigated the impact of NSBB‐intake at TIPS‐placement on periinterventional cirrhosis‐associated complications and continued NSBB‐treatment after discharge on complications including hepatic decompensation and mortality during 1‐year follow‐up, employing multivariable competing‐risk‐analyses. In a prospective cohort including 45 patients, we performed a comprehensive analysis of SI analysing 48 soluble inflammatory markers (SIMs) at baseline plus 3 and 6 months after TIPS‐insertion.Results: Overall, 175 (57.4%) patients received NSBB‐therapy prior to TIPS‐insertion; upon discharge, this decreased to 131 (22.9%), with 36 (27.5%) discontinuing NSBB within 1‐year follow‐up. Neither NSBB‐therapy at TIPS‐insertion nor treatment‐continuation after discharge were associated with lower risks for hepatic decompensation, individual cirrhosis‐associated complications or mortality neither in the periinterventional period nor during follow‐up. Similarly, in the prospective cohort NSBB‐intake was not linked to lower levels or a more prominent change of WBC, CRP or any other SIM at any of the investigated time points.Conclusion: NSBB‐therapy at the time of TIPS‐insertion and its (dis‐)continuation afterwards seems to have no significant impact on SI, development of hepatic decompensation and survival.

12 June 2024 in Clinical Nutrition
Verified
Journal Article
Open access
LBLaura Buttler
Laura Buttler
ATAnja Tiede
Anja Tiede
MGMarie Griemsmann
Marie Griemsmann
HSHannah Schneider
Hannah Schneider
JMJim Mauz
Jim Mauz
KHKatharina Luise Hupa-Breier
Katharina Luise Hupa-Breier
Thiamine and folic acid malnutrition is highly frequent in patients with decompensated alcohol-related liver cirrhosis (aLC). Current guidelines therefore recommend vitamin supplementation in these patients. However, implementation and its impact on the clinical outcome remains unknown. Therefore, we aimed to analyze the use of thiamine and folic acid and their effects on mortality and morbidity in patients with decompensated aLC. A number of 289 consecutive patients with decompensated aLC who received a paracentesis at Hannover Medical School between 2011 and 2023 were retrospectively investigated. The use of folic acid and thiamine-containing supplements was assessed in the discharge medication. Patients were followed for up to one year regarding liver transplant (LTx)-free survival and the incidence of hepatic encephalopathy, infections and hepatic decompensation requiring rehospitalization. Median baseline MELD was 15, median age 56.6 years. 73.0% (n = 211) were male patients. At hospital discharge, thiamine-containing supplements and folic acid were prescribed to 48.1% (n = 139) and 18.0% (n = 52) patients, respectively. Neither thiamine nor folic acid prescription were linked to improved clinical outcomes within 90 days. However, folic acid intake was associated with a higher one-year LTx-free survival (HR = 0.48; p = 0.04) in the multivariable analysis. Furthermore, folic acid substitution was linked to a decreased risk of rehospitalization within one year (HR = 0.55; p = 0.01) in the multivariable competing risk model. In contrast, thiamine prescription did neither affect LTx-free survival nor the here investigated liver-related complications. Folic acid, but not thiamine substitution was linked to an improved outcome in patients with decompensated aLC.